ROSWELL, GA (PRWEB) DECEMBER 11, 2017

Emerging Implant Technologies GmbH (EIT), a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application by utilizing additive manufacturing, announces that it has now successfully completed the contracting process with HealthTrust related to an HCA contract and is now able to offer all interbody products for Cervical, ALIF, TLIF and PLIF procedures in the 177 hospitals and 119 freestanding surgery centers located throughout the United States.

EIT Cellular Titanium® is a 3D printed porous titanium structure that has been designed according to scientific insights on ideal pore shape and size to optimize cell proliferation and bone ingrowth.

With the addition of this contract, EIT is poised to continue its aggressive growth pattern in the United States. EIT believes that this will create more unique opportunities to work with HCA surgeons to evaluate and take advantage of the validated structure and many other unique features that differentiate EIT from other 3D printed products.

The contract approval was pursued and successfully completed by Ortho Sales Partners. Josh Sandberg, President of OSP said, “This is a huge milestone that we have been able to help achieve at an unusually early stage in EIT’s development. That is a credit to the strength of this product offering and we are excited about the opportunity to work with HCA facilities in helping them lower the overall cost of these spine procedures.”

“EIT´s goal is to improve spine care using the advantages of 3D printing technology and cope with given pricing and reimbursement structures. We are delighted that HCA/HealthTrust is interested in working with EIT. This will help us to get quicker market access in the United States” said Guntmar Eisen, cofounder and CEO of EIT.

In addition to the contract, EIT is currently finalizing an action plan with HCA leadership to understand the economic impact this novel technology will have on fusion rates, implant costs and the need for high cost osteobiologics. Further details of this proposal will be announced at a later time.
________

About EIT

EIT is the first medical device manufacturer to exclusively focus on implants for spinal alignment, that are designed according to latest published science on optimal bone ingrowth in porous titanium scaffolds and produced with additive manufacturing methods. EIT was founded in 2014 by Hans Eekhof and Guntmar Eisen.

The EIT implants are made of EIT Cellular Titanium®, that addresses the clinical shortcomings of the current cage designs and materials (non-fusion, biocompatibility, subsidence, migration and imaging distortion), thereby obtaining very promising fusion results and improved clinical outcome due to the qualities of the porous 3-D printing of titanium. The highly porous titanium scaffold ensures extensive bone ingrowth as a result of its specific design and elasticity close to the cancellous bone. Due to its unique design with a porosity of 80% the EIT implants ensure uncompromised imaging on X-ray and MRI and enabling excellent follow up on defining bone ingrowth and fusion with CT.

A complete portfolio of Smart Spinal Implants™ based on EIT Cellular Titanium® is available for the cervical and lumbar spine, with an extensive choice in footprint sizes, heights and lordosis angles to support the recreation of sagittal balance and alignment. Since 2014 over 12.000 EIT cases have been performed in over 15 markets globally.

OR AKIVA, Israel, Dec. 4, 2017 /PRNewswire/ — Expanding Orthopedics Inc. (EOI), a privately held medical device company focused on developing and commercializing innovative expandable devices for spine surgery, is proud to announce that Dr. Adam Lewis of Jackson MS is the first surgeon in Mississippi to adopt the FLXfit™ 3D Expandable Cage as his treatment of choice for MIS TLIF procedures. Dr. Lewis is a prominent neurosurgeon and founder of the Jackson Neurosurgery Clinic in Jackson MS.  He is a pioneer in MIS spine surgery and leads the shift to less invasive fusion procedures.

Dr. Lewis stated “The spine market is shifting towards MIS outpatient care. Instrumentation, implants, and techniques need to rapidly evolve to enable this revolution.” He commented, “I am a great believer in expandable cages, especially for MIS procedures where surgical access is limited. A low profile implant which can be easily inserted and expands in-situ is critical to obtain the best outcome.” Dr. Lewis noted, “Most expandable cages I have used provide only a partial solution as they have a small footprint and expand only in one plane. They don’t offer sufficient support and sagittal balance restoration.”

Dr. Lewis further explains, “The FLXfit™ family of expanding TLIF cages are ideal for MIS fusion surgery as they enable a best in class expandable cage through a small tube. The unique articulation feature allows me to place a traditional linear shape cage through a tube and achieve an ALIF like footprint.  This minimizes blood loss and surgical trauma while offering the best possible outcome.”  He concluded, “The initial observations on my first series of patients show very promising results. I now have the ability to dial-in up to 15 degrees of lordosis and significantly restore the natural lumbar curve.  Additionally, patients have a much larger, more stable implant which reduced pain and provide faster return to normal daily activities.”

Ofer Bokobza, CEO of Expanding Orthopedics, commented “We are honored to work with Dr. Lewis.  Engaging with a leading MIS surgeon    like Dr. Lewis provides us with a collaborative expertise that enhances our ability to continuously improve the system”. Ofer noted “Dr. Lewis’ choice to employ FLXfit™ for his MIS fusion surgery helps validate our mission to restore and retain lumbar lordosis and be a prominent leader in addressing sagittal balance.

About Expanding Orthopedics Inc.

Expanding Orthopedics Inc. is medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients’ outcome. The Company is spearheaded by a seasoned management team, and is advised by a prominent team of spine surgeons. EOI owns a broad patent portfolio around anatomically fit, expandable devices for enhanced stability through a minimally invasive approach.

Contact info:
David Elkaim, VP Marketing and Sales
E-mail: david@xortho.com
Phone: (347) 3219683

View original content:http://www.prnewswire.com/news-releases/dr-adam-lewis-to-adopt-eois-flxfit-articulated-and-expandable-cages-as-his-treatment-of-choice-for-mis-tlif-300565784.html

AUDUBON, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the results of its seven-year clinical trial follow-up that demonstrate superiority of the SECURE-C^® Cervical Artificial Disc over the current standard for the treatment of cervical disc disease, anterior cervical discectomy and fusion (ACDF), based on overall success.  SECURE-C^® is designed for disc reconstruction and motion preservation at the operated disc level, unlike traditional motion-eliminating fusion surgery.

“The long-term evidence shown in this study confirms the outstanding results I have seen in my own patients treated with SECURE-C^®,” said Dr. William Beutler, neurosurgeon at the Pennsylvania Spine Institute. “SECURE-C^®’s integrated keel is designed for optimal placement and migration resistance, allowing my patients to better maintain their active lifestyles. SECURE-C^® is proven to be a superior treatment option to fusion for patients with cervical disc disease.”

The prospective, randomized Investigational Device Exemption (IDE) trial involved a total of 380 study subjects (240 investigational and 140 control) to compare the safety and effectiveness of SECURE-C^® to ACDF using a cervical plate and structural allograft for patients with intractable symptomatic cervical disc disease (SCDD) at a single level in the cervical spine.  At seven years post-surgery, SECURE-C^®patients reported greater overall satisfaction with surgery and exhibited the following:

• Statistically superior composite overall success results (86.3%) compared to ACDF patients (70.0%);
• Greater improvement in pain and function based on the Neck Disability Index (90.4%) versus ACDF patients (86.0%);
• Lower rate of subsequent surgery (4.2%) at the original treated level compared to ACDF patients (15.3%); and
• Lower rate of adjacent level surgery (4.2%) versus ACDF patients (16.0%).

“The seven-year clinical study findings provide further evidence for statistical superiority of SECURE-C^® to ACDF in terms of overall success, bolstering the long term data on cervical arthroplasty,” said Kelly Baker, Ph.D., Senior Vice President of Regulatory and Clinical Affairs. “We are excited to release these findings as Globus continues to bring innovative engineering and superior clinical devices to spine surgeons and their patients.”

Indications 
The SECURE-C^® Cervical Artificial Disc is indicated in skeletally mature patients for reconstruction of the disc at one level from C3-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain or myelopathy due to a single-level abnormality localized to the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. The SECURE-C^® Cervical Artificial Disc is implanted using an anterior approach. Patients should have failed at least 6 weeks of conservative treatment prior to implantation of the SECURE-C^® Cervical Artificial Disc.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional   information can be accessed at http://www.globusmedical.com

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Dan Scavilla
Senior Vice President and Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

LEESBURG, Va., Nov. 30, 2017 (GLOBE NEWSWIRE) — K2M Group Holdings, Inc. (NASDAQ:KTWO) (the “Company” or “K2M”), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance^™, today announced the completion of 300 surgical cases using the RHINE^™ Cervical Disc System*. The announcement was made during the 12^th Annual Meeting of the German Spine Society, occurring November 30–December 2, 2017, in Stuttgart, where the Company will exhibit its comprehensive product portfolio and the Balance ACS^® (BACS^®) platform at Stand #73.

The RHINE Cervical Disc System* is an artificial disc replacement that features a one-piece compressible polymer core design with dome-shaped, plasma-coated endplates and a central-split keel. Proprietary molding technology is incorporated to minimize wear between the polymer core and metal endplates. The system’s instrumentation simplifies spinal surgery by integrating trialing and keel cutting into one instrument. A built-in adjustable stop allows for customized anterior or posterior positioning of the disc based on surgeon preference.

“The RHINE Cervical Disc was designed to mimic the characteristics of a normal healthy disc,” said Dr. Ardavan Ardeshiri, a neurosurgeon and spine surgeon at the Hessing Klinik in Augsburg, Germany, and an Investigator of the RHINE Cervical Disc Prospective Observational Clinical Study. “The product design, combined with easy-to-use modular instrumentation and a simple surgical technique, provides surgeons with an advanced solution for cervical disc replacement.”

The RHINE Cervical Disc Prospective Observational Clinical Study is presently gathering additional operative data and feedback to confirm device performance, including radiographic data and clinical outcomes.

“K2M is proud to acknowledge the 300 surgeries that have been completed using our RHINE Cervical Disc System*,” said K2M Chairman, President, and CEO Eric Major. “RHINE, which received a CE Mark last year, is an advancement in cervical disc technology, and its continued commercialization and clinical validation in Europe is an important piece of our corporate strategy. We look forward to showcasing RHINE, our Balance ACS platform, and many of our innovative spinal solutions at this year’s meeting of the German Spine Society.”

K2M to Exhibit Spinal Innovations and Balance ACS Platform

In addition to the RHINE Cervical Disc System*, K2M will showcase differentiated spinal technologies from its comprehensive complex spine, minimally invasive, and degenerative portfolios. These products include the 3D-printed CASCADIA^™ Interbody Systems featuring K2M’s Lamellar 3D Titanium Technology^™, the EVEREST^® Minimally Invasive XT Spinal System, the NILE^® Alternative Fixation and NILE Proximal Fixation Spinal Systems, the MESA^® Deformity Spinal System, the SAHARA^® AL Expandable Stabilization System, and more.

K2M will also feature its Balance ACS platform, which provides solutions focused on achieving balance of the spine by addressing each anatomical vertebral segment with a 360-degree approach to the axial, coronal, and sagittal planes, emphasizing Total Body Balance as an important component of surgical success. K2M will demo the BACS Surgical Planner, a surgical image measuring technology that assists in planning and preoperative implant selection.

For more information on K2M’s complete product portfolio, visit www.K2M.com. For more information on Balance ACS, visit www.BACS.com.

*This product is intended for export and is not sold or offered for sale in the United States.

About K2M

K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market. For more information, visit www.K2M.com and connect with us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements that reflect current views with respect to, among other things, operations and financial performance.  Forward-looking statements include all statements that are not historical facts such as our statements about our expected financial results and guidance and our expectations for future business prospects.  In some cases, you can identify these forward-looking statements by the use of words such as, “outlook,” “guidance,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words.  Such forward-looking statements are subject to various risks and uncertainties including, among other things: our ability to achieve or sustain profitability in the future; our ability to demonstrate to spine surgeons the merits of our products and retain their use of our products; pricing pressures and our ability to compete effectively generally in our industry; collaboration and consolidation in hospital purchasing; inadequate coverage and reimbursement for our products from third-party payors; lack of long-term clinical data supporting the safety and efficacy of our products; dependence on a limited number of third-party suppliers; our ability to maintain and expand our network of direct sales employees, independent sales agencies and international distributors and their level of sales or distribution activity with respect to our products; proliferation of physician-owned distributorships in the industry; decline in the sale of certain key products; loss of key personnel; our ability to enhance our product offerings through research and development; our ability to manage expected growth; our ability to successfully acquire or invest in new or complementary businesses, products or technologies; our ability to educate surgeons on the safe and appropriate use of our products; costs associated with high levels of inventory; impairment of our goodwill and intangible assets; disruptions to our corporate headquarters and operations facilities or critical information technology systems, distributors or surgeon users; our ability to ship a sufficient number of our products to meet demand; our ability to strengthen our brand; fluctuations in insurance cost and availability; our ability to comply with extensive governmental regulation within the United States and foreign jurisdictions; our ability  to maintain or obtain regulatory approvals and clearances within the United States and foreign jurisdictions; voluntary corrective actions by us or our distribution or other business partners or agency enforcement actions; recalls or serious safety issues with our products; enforcement actions by regulatory agencies for improper marketing or promotion; misuse or off-label use of our products; delays or failures in clinical trials and results of clinical trials; legal restrictions on our procurement, use, processing, manufacturing or distribution of allograft bone tissue; negative publicity concerning methods of tissue recovery and screening of donor tissue; costs and liabilities relating to environmental laws and regulations; our failure or the failure of our agents to comply with fraud and abuse laws; U.S. legislative or Food and Drug Administration regulatory reforms; adverse effects of medical device tax provisions; potential tax changes in jurisdictions in which we conduct business; our ability to generate significant sales; potential fluctuations in sales volumes and our results of operations over the course of the year; uncertainty in future capital needs and availability of capital to meet our needs; our level of indebtedness and the availability of borrowings under our credit facility; restrictive covenants and the impact of other provisions in the indenture governing our convertible  senior notes and our credit facility;  continuing worldwide economic instability; our ability to protect our intellectual property rights; patent litigation and product liability lawsuits; damages relating to trade secrets or non-competition or non-solicitation agreements; risks associated with operating internationally; fluctuations in foreign currency exchange rates; our ability to comply with the Foreign Corrupt Practices Act and similar laws; our ability to implement and maintain effective internal control over financial reporting; potential volatility in our stock price; our lack of current plans to pay cash dividends; our ability to take advantage of certain reduced disclosure requirements and exemptions as a result of being an emerging growth company; increased costs and additional regulations and requirements as a result of no longer qualifying as an emerging growth company as of December 31, 2017; potential dilution by the future issuances of additional common stock in connection with our incentive plans, acquisitions or otherwise; anti-takeover provisions in our organizational documents and our ability to issue preferred stock without shareholder approval; potential limits on our ability to use our net operating loss carryforwards; and other risks and uncertainties, including those described under the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC and our Quarterly Report filed with the SEC on August 2, 2017, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.  Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and our filings with the SEC.

We operate in a very competitive and challenging environment.  New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this release.  We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this press release relate only to events as of the date on which the statements are made.  We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.  We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Unless specifically stated otherwise, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions we may make.

Media Contact:
Zeno Group on behalf of K2M Group Holdings, Inc.
Christian Emering, 212-299-8985
Christian.Emering@ZenoGroup.com

Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.
Mike Piccinino, CFA, 443-213-0500
K2M@westwicke.com